HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Management of hemosiderosis complicated by coexistent anemia with recombinant human erythropoietin and phlebotomy.

Abstract
Patients with hemosiderosis who also suffer from coexistent anemia may be unable to tolerate frequent phlebotomies needed for depletion of body iron stores. Chelation therapy, an alternative approach, may be unsuitable for some patients due to allergic reactions, poor response or intolerance of long-duration subcutaneous administration. The use of recombinant human erythropoietin in such patients could increase the hematocrit and improve exercise tolerance allowing for more frequent phlebotomies. We report the successful use of this combined approach in two such patients.
AuthorsS Bilgrami, A Bartolomeo, V Synnott, F R Rickles
JournalActa haematologica (Acta Haematol) Vol. 89 Issue 3 Pg. 141-3 ( 1993) ISSN: 0001-5792 [Print] Switzerland
PMID8362602 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Recombinant Proteins
  • Erythropoietin
Topics
  • Aged
  • Anemia, Refractory (etiology, pathology, therapy)
  • Bloodletting
  • Combined Modality Therapy
  • Erythropoietin (therapeutic use)
  • Female
  • Hemosiderosis (complications, pathology, therapy)
  • Humans
  • Male
  • Middle Aged
  • Recombinant Proteins (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: